UPDATE : Friday, August 7, 2020
상단여백
HOME Device/ICT
Chunlab launches new platform to trace mutated Covid-19 virus
  • By Shim Hyun-tai
  • Published 2020.07.17 17:44
  • Updated 2020.07.17 17:44
  • comments 0

Microbiome database company Chunlab said it has launched "EzCOVID19," an epidemiological platform that can track the Covid-19 virus worldwide by analyzing the path of infection and mutation pattern.

EzCOVID19, a cloud-based platform for analyzing the Covid-19 virus developed by Chunlab's technology, can check the analysis results in 10 minutes by inputting the genome data from anywhere in the world.

Yoon Seok-hwan, Chunlab’s bioinformatics laboratory research director, explains the newly launched cloud-based analysis platform, EzCOVID19, at the company on Friday. (Chunlab)

Continuous mutation analysis can help predict future variants of Covid-19, diagnostic kits for the mutants, and development of vaccines and treatments as the platform can assess mutation quickly.

According to a recent study, the Covid-19 virus could mutate once every 12 days. The significance of tracking mutated Covid-19 virus is growing as the pandemic's end appears to take a while.

The company has preemptively opened EzCOVID19 in consideration of the global crisis such as the rapid spreading speed of Corona-19, the increasing number of patients with an unknown path of transmission, and the prediction of the second wave of the pandemic.

"We expect to seek cooperation with global pharmaceuticals as our platform EzCOVID19 can apply data-based platform technology to new infectious diseases that may occur in the future," said Yoon Seok-hwan, research director of bioinformatics laboratories at Chunlab.

Chunlab CEO Chun Jong-sik also said, "The launch of a global platform, which can confirm the spread and mutation of viruses quickly, will open an era where anyone can analyze data directly with NGS data.”

Anyone can use the platform service from anywhere in the world by accessing the EzCOVID19 website, https://covid19.ezbiocloud.net, the company said.

shim531@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>

Other articles by Shim Hyun-tai
iconMost viewed
Comments 0
More
Please leave the first comment.
여백
여백
여백
Back to Top